85 results on '"Boku, Narikazu"'
Search Results
2. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
3. Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines
4. Prediction of the peritoneal recurrence via the macroscopic diagnosis of the serosal invasion in patients with gastric cancer: Supplementary analysis of JCOG0110
5. Second gastric cancer after curative endoscopic resection of differentiated-type early gastric cancer: post-hoc analysis of a single-arm confirmatory trial
6. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
7. P1-6 Preoperative docetaxel, cisplatin, and 5-FU for resectable esophagogastric junction adenocarcinoma: Retrospective study
8. MO5-2 Retrospective study of nivolumab monotherapy for advanced esophageal squamous cell carcinoma
9. PSY8-2 Search of biomarkers and creation of innovative methods required for precision medicine for gastric cancer
10. ID: 3518404 METACHRONOUS GASTRIC CANCER AFTER CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION OF INTESTINAL-TYPE EARLY GASTRIC CANCER: POST HOC ANALYSIS OF JCOG0607
11. Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer
12. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)
13. Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position
14. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
15. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
16. Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A
17. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
18. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial
19. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
20. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
21. A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR)
22. Effect of definitive radiotherapy alone for the patients with esophageal squamous cell carcinoma
23. 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)
24. Clinical outcome of salvage chemotherapy after oxaliplatin based chemotherapy for metastatic small bowel adenocarcinoma
25. Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study
26. A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients
27. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
28. The human equilibrative nucleoside transporter1 evaluated by SP120 and 10D7G2 had the potential to predict the prognosis in the patients with pancreatic cancer treated with adjuvant gemcitabine: Collaborative study of the JASPAC 01 trial
29. Su1366 A NON-RANDOMIZED SINGLE-ARM CONFIRMATORY TRIAL OF ENDOSCOPIC SUBMUCOSAL DISSECTION TO EXPAND ITS INDICATION FOR EARLY GASTRIC CANCER OF UNDIFFERENTIATED TYPE: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1009/1010)
30. Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases
31. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial
32. Docetaxel Plus Cisplatin and S-1 versus Cisplatin and S-1 in Patients with Advanced Gastric Cancer (JCOG1013): An Open-Label, Randomised, Phase 3 Trial
33. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score–matched analysis
34. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
35. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
36. Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer
37. Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated advanced gastric carcinoma
38. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer
39. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
40. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)
41. 4 Courses and 8 Courses of S-1 Adjuvant Chemotherapy for Pathological Stage II Gastric Cancer JCOG1104 (OPAS-1): A Phase 3, Open-Label, Non-Inferiority, Randomised Trial
42. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
43. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
44. Reply
45. Risk Factor Analyses of Severe Cicatricial Stricture after Chemoradiotherapy for Stage II/III (T3) Esophageal Carcinoma
46. WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP
47. Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis From Colorectal Cancer
48. Does Repeated Lung Resection Provide Long-Term Survival for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter Study
49. Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size
50. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.